Abstract Even though much progress has been made towards understanding the molecular nature of glioma, the survival rates of patients affected by this tumour have not changed significantly over recent years. Better knowledge of this malignancy is still needed in order to predict its outcome and improve patient treatment. VAV1 is an GDP/ GTP exchange factor for Rho/Rac proteins with oncogenic potential that is involved in the regulation of cytoskeletal dynamics and cell migration. Here we report its overexpression in 59 patients diagnosed with high-grade glioma, and the associated upregulation of a number of genes coding for proteins also involved in cell invasion-and migration-related processes. Unexpectedly, immunohistochemical experiments revealed that VAV1 is not expressed in glioma cells. Instead, VAV1 is found in non-tumoural astrocyte-like cells that are located either peritumouraly or perivascularly. We propose that the expression of VAV1 is linked to synergistic signalling cross-talk between cancer and infiltrating cells. Interestingly, we show that the pattern of expression of VAV1 could have a role in the neoplastic process in glioblastoma tumours.
Introduction
High-grade gliomas (HGGs), which include glioblastomas (GBMs) and anaplastic astrocytomas (AAs), are the most common intrinsic brain tumours in adults and are nearly always fatal. Recently, progress towards understanding the molecular basis of these tumours has been made due to the availability of large-scale genomic approaches and to the development of new bioinformatic tools. As a result, we now have valuable new information about glioma classification, tumour subclasses, progression markers and disease outcome predictors [1] [2] [3] [4] [5] . These studies have also revealed genes whose expression is specifically linked to the grade and progression status of tumours [6, 7] . In contrast to this progress at the molecular level, the development of new surgical techniques as well as Electronic supplementary material The online version of this article (doi:10.1007/s11060-012-0936-y) contains supplementary material, which is available to authorized users. chemotherapy and radiotherapy strategies has had little impact on survival rates of HGG patients [8] . Indeed, most GBM multiforme patients will die within 12 months of their diagnosis, a dramatic statistic that has not changed significantly over many years [9] .
Members of the Rho/Rac family of Ras-like GTPases are key mediators of cytoskeletal organisation and dynamics, participating in processes related to cell shape, migration and adhesion [10, 11] . As is the case for most Ras family members, the activity of these proteins is modulated during signal transduction events by the differential binding of guanosine nucleotides. In non-stimulated cells, these GTPases are bound to GDP in an inactive conformation [12] . Upon cell stimulation, Rho/Rac proteins bind GTP, leading to a conformational change that allows the engagement of proximal effectors and the subsequent activation of specific biological programs, including cytoskeletal change, modification of cell shape, cell motility, adhesion and many cell-type-specific functions [11, 13] . In addition to their important role in normal physiological processes, these proteins and their signalling pathways have been shown to be important for the progression of many diseases, including cancer [13] [14] [15] [16] [17] . Although these proteins have not been found to be mutated in cancer, it is currently assumed that they can become chronically upregulated in this pathology due to the formation of autocrine loops, the indirect stimulation by other oncoproteins (e.g. Ras and protein tyrosine kinases) and by the deregulation of either positive (GDP/GTP exchange factors) or negative (GTPase-activating proteins) regulatory molecules [11, 13] . Recent, it was reported the suggested effects of deregulated RHo GTPase signalling in brain tumour malignancy [18] .
VAV proteins are one of the best-known families of Rho/Rac activators [10] . These proteins work as GDP/GTP exchange factors for Rho/Rac proteins, allowing the rapid transition of these GTPases from the inactive to the active state upon cell stimulation [19] . The number of VAV family genes depends on the evolutionary stage of the species. In invertebrates, there is a single VAV locus, whereas, in vertebrates, there are three loci that encode the proteins known as VAV1, VAV2 and VAV3 [20] . An interesting and unique feature of all these proteins is that their GDP/GTP exchange activity is regulated by direct tyrosine phosphorylation [19] . As a consequence, VAV proteins are a common link between membrane receptors with intrinsic or associated tyrosine kinase activity and Rho/Rac GTPases [21] . The VAV family was initially identified due to the transforming activity of the first member isolated, the VAV1 oncogene [22] . Since then, many reports have been published linking the constitutive activity of these proteins to tumourigenesis [21] . Likewise, there are a number of reports indicating the overexpression or hyperactivation of VAV family proteins in certain types of cancer, such as that of the pancreas (VAV1) [23] , breast (VAV3) [24] , lung [25] and chronic lymphocytic leukaemia (VAV1) [15] and glioma (VAV3) [26] . Despite this evidence, there is still little information regarding the actual involvement of VAV proteins in human tumours or their value as potential prognostic factors. In the present report, we demonstrate the expression of the VAV1 protooncogene, but not of VAV2 or VAV3 proto-oncogenes, in the microenvironment of HGGs, especially those associated with high invasive potential.
Materials and methods

Patients
The study was approved by our institution's Review Board and Bioethical Committee. Informed consent was obtained from each subject participating in the study.
The present study included 59 patients who were diagnosed with a HGG in the Neurosurgical Service of the Salamanca University Hospital, according to standard WHO criteria. Forty-nine of these patients had a glioblastoma multiforme (GBM, grade IV glioma) while the remainder had AA (grade III glioma). The median age of patients was 65 years (range, 34-76 years) and disproportionately more were men (66 %) than women. Tumours were most frequently located in the temporal (42 %) and frontal (24 %) lobes. Total resection was performed in 36 patients. The median overall survival time of the whole series was 9 months (95 % CI, 7-12 months). Progressionfree survival (PFS; defined as the time from the initial operation to the development of progressive disease on a CT scan or until the last follow-up) was 6 months (range, 7-12 months). At the time of the study, most of patients (96 %) were already dead (Table 1) .
Immunohistochemical analyses of VAV1 status of all patients were carried out. Comparative genomic hybridisation was also carried out to determine the chromosomal status of 46 GBM patients. Gene expression profiles were studied in 32 patients (22 with GBM and 10 with AA diagnoses).
Methods
Oligonucleotide microarray analyses
Total RNAs were extracted using the Triazol reagent (Life Technologies, Gaithersburg, MD, USA) and purified with the RNeasy Mini kit (Qiagen, Valencia, CA, USA). The integrity of RNA samples obtained was assessed using the 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). Labelled RNAs were then fragmented and hybridised to HU-133A oligonucleotide arrays (Affymetrix, Santa Clara, CA, USA) according to standard Affymetrix protocols. After hybridisation and washes, arrays were scanned using the Gene Array Scanner (Affymetrix), and the expression value for each probe set calculated using MAS 5.0 software (Affymetrix). All examples had a scaling factor of less than three-fold and 3 0 /5 0 of GAPDH probe set \2.5. Gene levels were transformed to base two logarithms.
Microarray data analyses
To visualise clusters of genes with similar expression patterns, we used a hierarchical clustering method (Cluster and TreeView software) based on the average-linkage method with the centred correlation metric [36] . Multidimensional scaling (BRB Arrays Tools version 3.0) was also carried out, using Euclidean distance criteria [37] . Supervised learning using the significant analysis of microarrays (SAM) algorithm [38] was employed to identify genes with statistically significant changes in expression between classes. All data were permuted over 100 cycles by using the two-class (unpaired) and multiclass response format. Significant genes were selected based on the lowest false-discovery ratio (between 0.6 and 0.9). In addition, nonparametric tests such as the Wilcoxon rank sum test and the Kruskal-Wallis test for comparing more than two unpaired groups were done using PSAW Statistics 18.0
Functional annotation of microarray data
Probe sets showing significant change in expression were functionally annotated and grouped according to biological function criteria using GeneOntology biological process descriptions. The functional analysis to identify the most important biological mechanisms, pathways and functional categories in gene data sets was generated using the internetbased Ingenuity Pathway procedure (Ingenuity Systems, Mountain View, CA, USA; www.ingenuity.com) [39] . A functional network was considered significant when it fulfilled the following criteria: (i) a minimal score of 15; (ii) a minimum of 20 direct functional interactions among the network members.
Quantitative reverse transcription-PCR Total RNA was quantified in an RNA 6000 Nano Chip (Agilent Technologies) and quantitative PCR performed using the QuantiTect SYBR Green RT-PCR kit (Qiagen). We used two sets of probes to quantify VAV1 mRNA levels: pair A (5 0 -AACAACGGGAGGTTCACCCT-3 0 and 5 0 -GGTCCCTCATGGCATCCA-3 0 ) and pair B (5 0 -AGC CATTGGACCCTTTCTACG-3 0 and 5 0 -GCCATGGACAT AGGGCTTCA-3 0 ). Amplification was carried out using the iCycler apparatus (Bio-Rad Laboratories, California, USA). Data were analysed using the iCycler iQ Optical System Software, version 3.0a (Bio-Rad Laboratories). Primers for GAPDH were used as intersample normalising controls. Variations in expression of VAV1 mRNA were Table 1 Correlation between clinical data, localisation, genomics changes detected by CGH and FISH in GBM cases with VAV-1 expression by immunohistochemistry represented as the mean of the relative magnitude of change with respect to the VAV1 expression levels detected in sample #19209 with both pairs of oligonucleotide primers.
Immunohistochemical analyses
The VAV1 antibody was generated in rabbits using a synthetic peptide and purified by affinity chromatography in Bustelo's laboratory. This antibody recognises VAV1 proteins from humans and mice but not other VAV family members (unpublished data). For immunostaining, tissue sections were washed three times with xylene and once with 100 % ethanol, rehydrated by sequential changes in 80, 70 and 50 % ethanol and, lastly, incubated in phosphate-buffered saline (PBS). Each rehydrating step involved 3 min incubations with the indicated solutions. Endogenous peroxidases were quenched by the addition of a 3 % H 2 O 2 solution in methanol for 30 min at room temperature (RT). Tissue sections were then washed twice with PBS. Antigen was retrieved by incubation in 1 mM EDTA for 30 min at 37°C. Slides were washed twice in PBS and blocked in blocking buffer (Zymed, CA, USA) for 30 min at RT. Specimens were then incubated with the primary antibody (1:250 dilution) in blocking buffer. After a 1 h incubation at 37°C, slides were washed three times in PBS, incubated with a biotinylated secondary antibody for 30 min at 37°C, washed three times in PBS, incubated with horseradish peroxidase-streptavidin for 30 min at 37°C, washed three times in PBS, and developed using the AEC substrate (Zymed). Slides were then washed twice in water, counterstained with haematoxylin (Zymed), washed again in water, and mounted with GVA (Zymed). Samples were analysed by light microscopy and images acquired with an Axiophot imaging system (Zeiss, Munich, Germany).
Fluorescence in situ hybridisation analyses
Fluorescence in situ hybridisation (FISH) experiments were carried out on 40 cases of GBM multiforme (grade IV) positive for VAV1 expression. We performed dualcolour FISH analyses with locus-specific probes for centromere 7 (Abbott Molecular, Des Plaines) exactly as previously described [40] . Polysomies were defined when more than 10 % of the nuclei surveyed contained three or more CEP signals (chromosome-specific FISH probes that hybridise to highly repetitive human satellite DNA sequences, usually located near centromeres).
Immunohistochemistry and FISH in paraffin-embedded tumours
Sections measuring 4 lm were cut from routinely processed paraffin blocks and mounted on glass slides with a charged coating. Sections were dewaxed in xylene, then rehydrated using increasing concentrations of alcohol before being rinsed briefly in water. Slides were heated for 2 min in 1 mM EDTA (pH 9.0) in a microwavable pressure cooker. After antigen retrieval, slides were incubated for 1 h at RT in a moist chamber with a primary antibody diluted in PBS supplemented with 10 % foetal calf serum. Slides were incubated for 1 h with fluorochrome-conjugated antibodies to the appropriate IgG isotypes in a moist chamber in the dark. Finally, slides were washed three times in PBS containing 0.5 % Tween 20 before FISH analysis.
Degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) analyses
After the staining of tissue sections with VAV1 antibodies (see above), the regions of the tumour were identified, microdissected and collected using the PALM Ò microscope system (P.A.L.M. Microlaser Technologies, Munich, Germany). Genomic DNA was extracted as described by Isola et al. [41] , with modifications for small DNA amounts. Those included the resuspension of the microdissected sections in extraction buffer followed by digestion with proteinase K (0.6 mg/ml). All samples were resuspended in 10 ll of 10 mM Tris-HCl (pH 7.4) and 0.1 mM EDTA. DOP-PCR amplification was performed in two steps. For the first, low-stringency step, 1 ll of sample was added to 4 ll of buffer A (2.5 ll of 600 lM dNTPs; Roche, Pleasanton, CA, USA), 0.5 ll of 10 lM DOP primer 5 0 -CCGACTCGAGNNNNNNNATGTGG-3 0 , where n = A, C, G, or T) [42] and 1 ll of 59 Sequenase Reaction Buffer (Amersham, Cleveland, OH, USA). Reactions were performed using 5 cycles of 30°C for 5 min, 37°C for 2 min, and 96°C for 2 min, adding 0.65 units of Sequenase in each 30°C step. The first phase product was then subjected to the second step using 19 PCR buffer (Roche), 20 lM dNTP, 1.4 lM DOP primer and 2.5 units of Tag polymerase (Roche). PCR were run using 1 cycle at 95°C for 5 min, 35 cycles at 94°C for 1 min, 56°C for 1 min and 72°C for 2 min. The PCR was finalised with an extension cycle of 72°C for 5 min.
Comparative genomic hybridisation
Comparative genomic hybridisation (CGH) was performed as described elsewhere [43] . Briefly, tumour DNA (test DNA) was labelled with biotin-16-dUTP (Boehringer Mannheim, Mannheim, Germany) and the reference DNA was labelled with digoxigenin-11-dUTP (Boehringer Mannheim) using standard nick-translation reactions. After hybridisation for 1-2 days in a moist chamber at 37°C, post-hybridisation washes were performed to a stringency of 0.19 SSC at 42°C. Images were acquired with an epifluorescence microscope equipped with a cooled charge-coupled device camera (Nikon MDR1000, Melville, NY, USA). Images were analysed with Quips CGH software (QUIPS, Vysis, Downers Grove, IL, USA).
Statistical analyses
We used the SPSS 18.0 statistical program (SPSS Inc, Chicago, IL) for all analyses unless otherwise stated. Fisher's exact test was used to test for associations between pairs of genomic changes and between genomic changes and other experimental variables.
Results
Gene expression profiling identifies two groups of HGGs
A total of 32 patients (22 GBMs and 10 AAs) were studied using Affymetrix U133A oligonucleotide microarrays. Hierarchical unsupervised cluster analysis of the differentially expressed probe sets classified patients into two main branches on the basis of their transcriptomal profiles. The first group, referred to hereafter as group A, was composed exclusively of grade IV gliomas (Fig. 1) . The second group, referred to as group B, included the expression profiles of 20 patients (Fig. 1) . Group B was more heterogeneous than group A, and could be divided into two subgroups containing the expression profiles obtained from the 10 GBM or the 10 AA cases (Fig. 1 ). These clusters included 236 genes in total (Supplementary Table 1 ). It is of particular note that group A contained only upregulated genes, indicating that this patient subtype is associated with gene expression rather than repression events.
Unsupervised hierarchical clustering of our cases showed that group B was composed of nine classic, seven proneural, two neural and two mesenchymal subtype cases. However, in cluster A, nine cases were of the mesenchymal subtype, two were associated with the classic subtype and one case was proneural.
The functional annotation of those genes revealed different biological processes to be involved in the regulation of cell adhesion and cell growth. Genes involved in this class included those encoding Rho/Rac family members (RAC2, RHOG), positive Rho/Rac regulators (VAV1, DOK1) and negative Rho/Rac regulators (ARHGAP15 and ARHGAP14). In addition, we noted genes encoding proteins involved in immune and inflammatory responses that are usually expressed by macrophages, microglia and lymphocytes (Supplementary Table) .
These analyses revealed the differentially regulated genes to be grouped in two main interactive networks (Fig. 2) . One network comprised proteins loosely related to cytoskeletal dynamics, including integrin subunits, VAV1, upstream tyrosine kinases that phosphorylate and activate VAV1 (SYK, LYN, HCK) and VAV1 downstream elements (RAC2, ARHGDIB) (Fig. 2a) . A second network containing the JAK-STAT6 axis together with immune response-related proteins (i.e. CD74, MHC class II) was also detected in the transcriptome of GBM patients (Fig. 2b) .
VAV1 is expressed in HGGs
To independently validate the expression of VAV1 in GBM, we used RT-PCR analysis of nine HGG cases (2 AAs and 7 GBMs). In agreement with the microarray data, all GBM cases included in the transcriptomal group A significantly overexpressed VAV1 transcripts. By contrast, a case of GBM and two cases of AA whose transcriptomal profiles clustered with group B displayed no VAV1 mRNA overexpression (Fig. 3) . The implication of these results, prompted us to study the expression pattern of VAV1 protein in high-grade GBMs. To this end, we performed Fig. 1 Dendrogram from a hierarchical cluster analysis of high-grade gliomas. Two branches were observed. Grade III and grade IV glioma patients are represented in red and blue, respectively immunohistochemical analyses of paraffin-embedded tissue sections derived from 50 GBM patients using an anti-VAV1-specific antibody (see Methods). We observed VAV1 immunoreactivity in 92 % of all samples analysed. However, we observed marked heterogeneity of signal intensity, and density and localisation of VAV1-positive cells in the tumour. Thus, 54 % (27/50) of the GBMs analysed had weak VAV1 immunostaining (1 % of the tumour, or negative) whereas all other cases displayed VAV1 staining in 5 % or more of the cells screened. Likewise, we noticed that the density of VAV1-positive cells ranged from less than 1 % to more than 5 % of cells in the tumour samples under study. The characterization and clinical data of patients were included on Table 1 .
The cytological analyses showed that VAV1-positive cells were characterised by a starry morphology, with irregular, neurite-like projections of variable length (Fig. 4a) . Occasionally, they exhibited a polygonal morphology (Fig. 4b) . These cells had large cytoplasms and nuclei compared with the surrounding, VAV1-negative cells. Their nuclei featured variable atypia, smooth nuclear contours, fine chromatin and occasional nucleoli. The cytological appearance of these GFAP-positive cells leads to the conclusion that they are infiltrating astrocytes and not tumour cells. Consistent with these observations, in two cases with VAV-1 staining in more than 5 % and ?7 and -10 by CGH, we combing CGH with the techniques of DOP-PCR and LCM ( Supplementary  Fig. 1 ).This analysis showed that VAV-1-positive cells had experienced no genomic changes.
Consistent with these observations, FISH analyses using chromosome 7-specific probes indicated that VAV-1-positive cells displayed two signals for chromosomes 7 and that, therefore, they were unlikely to represent glioma cells. We also found that VAV1-positive cells were located around the normal and GBM-triggered vasculature (18 % of cases) or in the surrounding tumour mass (20 % of cases) Fig. 2 Genetic networks based on the differences observed between groups A and B described in Fig. 1 . Network (a) contains genes encoding proteins involved in cellular processes including cell growth, differentiation and migration. Network (b) is composed of genes coding for proteins associated with the immune response and MCH class II. In all cases the acre colour coded according to their ''d'' score (red, overexpression). Nodes represent genes, with their shape representing the functional class of the gene product, and edges indicating the biological relationship between the nodes (see legends in inset figure) Fig. 3 Expression of VAV1 mRNA in anaplastic astrocytoma and glioblastoma multiforme patients determined by real-time quantitative RT-PCR. VAV1 expression was stronger in the patients included in cluster A (all of which had a diagnosis of GBM) (Fig. 4c, d ), a result that also argues against the expression of VAV1 in glioma cells.
There were some interesting patterns of expression of VAV1 detected by immunohistochemistry and microarrays. Thus, in 28 (22 GBM and 6 AA) cases was possible to associate the expression profile with the expression pattern of VAV1. In 31 % (8/22) of cases with GBM displayed VAV1 staining in 5 %. We have observed that 50 % of patients included in transcriptomal group A expressed VAV1 protein in more than 5 % of cells, while a significantly lower percentage (20 %) of patients in group B expressed VAV-1.
Discussion
We have identified differences in the expression of 226 genes in patients diagnosed as HGGs. The gene expression allowed the patients to be classified into two main groups, one composed exclusively of grade IV gliomas and a second, more heterogeneous group could be further divided into subgroups associated with a specific subset of GBM and AA patients (Fig. 1) . Interestingly, the former group (group A) had consistently upregulated specific loci that encoded proteins commonly involved in signalling pathways related to cell growth, cell adhesion and the immune system. Some of the genes identified in our study have been previously associated with gliomas, including ferritin, granulin, lipoxygenase-5, IL4 receptor, STAT6, LYN and TGFB1 [27] [28] [29] [30] [31] . Taken together, these results indicate that the transcriptional profiles are associated with molecular and/or biological aspects of advanced glioma cases.
A consistent biological blueprint of patient group A is the presence of genes encoding proteins directly linked to integrin signals, cell adhesion and migration. These include some integrin subunits, downstream tyrosine kinases of the [32] . However, recent results have shown that their expression appears to be critical to ensure the oncogenic activity of some Rho/Rac family proteins such as Cdc42 [33] . This implies that they also act positively on Rho/Rac proteins, although we do not know whether this is due to their involvement in Rho/Rac GTPase trafficking, downstream signalling or Rho/Rac activation. So, into these proteins with catalytic activity in downstream elements of the Rh0/Rac pathways are the VAV1 proteins. Expression profile showed that VAV1 are overexpressed in a group of high grade glioma A caveat commonly associated with microarray analysis of tumours, including glioma [34] , is that most samples are heterogeneous since they include tumoural and stromal cells, and invading cells such as neutrophils and lymphocytes. It is therefore important to verify whether the gene expression changes identified by transcriptomal analyses correspond to bona fide changes in the transcriptome of cancer cells, to expression patterns triggered by cancer cells in the surrounding stroma or to the infiltration of new cell types in the tumour mass. The present report exemplifies this problem well, since we have observed that the VAV1 transcripts in HGG in 46 % of GBM by immunohistochemical. However, this ''overexpression'' of VAV1 transcripts in HGG is not due to the deregulation of their gene but, instead, to the infiltration of GAFP-positive, astrocytelike cells into the vicinity of tumour cells.
Whereas the identification of gene markers specifically expressed in cancer cells is of obvious biological interest, the identification of genes differentially located in stromal and infiltrating cells may also be of interest, since they can reveal intrinsic biological features of the tumour that may, in turn, be of diagnostic and/or prognostic interest. In this regard, there is mounting evidence that the manipulation of normal cells by tumoural cells is a key event in cancer progression [35] . Consistent with this idea, we observed that the localisation of VAV1-positive cells is a good prognostic factor, since GBM patients with perivascularly localised VAV1-positive cells had higher survival rates than those displaying VAV1-positive cells in other tumour locations. It is therefore likely that, once attracted to those sites by cancer-derived signals, these astrocyte-like cells will provide additional signals that, by paracrine or cell-cell interactions, favour the malignant behaviour of glioma cells over the long term. It will be interesting to investigate the signals that can regulate this biological cross-talk.
Our studies have detected only VAV1 as being a differentially regulated gene in our subset of HGGs. This is in contrast to a previous study showing that VAV3 is overexpressed in glioma [26] . This discrepancy can be explained if we consider the type of analysis conducted in each case. In the latter study, differentially expressed genes were indentified by comparing glioma samples with those derived from non-tumoural tissue and low-grade astrocytoma. In our case, we have focused exclusively on gene fingerprints specific to the various types of glioma patient. Thus, it is likely that VAV3 would appear to be overexpressed in our study if our samples were compared with healthy tissue or other brain tumours, rather than among themselves. In any case, these two studies highlight an interesting specialisation of VAV family members in human glioma: whereas VAV3 acts within glioma cells, VAV1 works at the level of infiltrating astrocytes. Further work in this area needs to address the prognostic and diagnostic value of VAV1 expression and of the transcriptomal fingerprints identified in the present study.
